SANOFI-ADR
SNYNASDAQTrading Snapshot
- Day Range
- $39.86 β $40.66
- 52-Week Range
- $40.66 β $52.68
- Volume
- $3.84B
- Avg Volume
- $2.60B
- Shares Outstanding
- 2.40B
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $46.72B
- Last Q Revenue
- $12.30B
- P/E Ratio
- 22.0
- P/S Ratio
- 1.8x
- EPS (TTM)
- $1.65
- Dividend Yield
- 11.61%
- Dilution (1yr)
- β2.6%
Why Investors Own SNY
- βHigh-growth profile β revenue up -0.7% YoY with expanding US Equity exposure.
- βHealthy economics β 28% gross margin and 14% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SANOFI-ADR
SNYAbout SANOFI-ADR
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
Sanofi (NASDAQ: SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Sanofi Eyes β¬25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company's executive vice

Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive
Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue bas